Which has better earnings and valuation, CALA or GNCA?

Genocea Biosciences has higher revenue and earnings than Calithera Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calithera Biosciences N/A N/A -$39.65M N/A N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is CALA or GNCA more profitable?

Calithera Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Calithera Biosciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Which has preferable earnings and valuation, PXMD or CALA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Calithera Biosciences N/A N/A -$39.65M N/A N/A

Is PXMD or CALA more profitable?

Calithera Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Calithera Biosciences N/A N/A N/A

Do analysts recommend ADTX or CALA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Calithera Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, ADTX or CALA?

Calithera Biosciences has lower revenue, but higher earnings than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Calithera Biosciences N/A N/A -$39.65M N/A N/A

Which has stronger valuation & earnings, ARDS or CALA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A Calithera Biosciences N/A N/A -$39.65M N/A N/A

Is ARDS or CALA more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Calithera Biosciences N/A N/A N/A

Which has stronger earnings & valuation, GNCAQ or CALA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Calithera Biosciences N/A N/A -$39.65M N/A N/A

Is GNCAQ or CALA more profitable?

Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Calithera Biosciences N/A N/A N/A

Calithera Biosciences (CALA) Competitors

$0.0004 0.00 (0.00%)

As of 07/2/2026

Compare

CALA vs. GNCA, PXMD, ADTX, ARDS, and GNCAQ

Should you buy Calithera Biosciences stock or one of its competitors? MarketBeat compares Calithera Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calithera Biosciences include Genocea Biosciences (GNCA), PaxMedica (PXMD), Aditxt (ADTX), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry.

How does Calithera Biosciences compare to Genocea Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Calithera Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

0.6% of Genocea Biosciences shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Genocea Biosciences	Neutral

Genocea Biosciences has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Calithera Biosciences has a beta of -1.36, suggesting that its stock price is 236% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Summary

Calithera Biosciences and Genocea Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Calithera Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Calithera Biosciences	N/A	N/A	N/A

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, meaning that its stock price is 236% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Calithera Biosciences	Neutral

Summary

PaxMedica beats Calithera Biosciences on 4 of the 7 factors compared between the two stocks.

How does Calithera Biosciences compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Calithera Biosciences has lower revenue, but higher earnings than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Calithera Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Calithera Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Calithera Biosciences	N/A	N/A	N/A

Aditxt has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, indicating that its share price is 236% less volatile than the broader market.

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Calithera Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Calithera Biosciences	Neutral

Summary

Aditxt and Calithera Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Calithera Biosciences compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Calithera Biosciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

Aridis Pharmaceuticals has a beta of 44.97, indicating that its share price is 4,397% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, indicating that its share price is 236% less volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Calithera Biosciences on 4 of the 5 factors compared between the two stocks.

How does Calithera Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Calithera Biosciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, suggesting that its share price is 236% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

Summary

Genocea Biosciences and Calithera Biosciences tied by winning 1 of the 2 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALA vs. The Competition

Export

Metric	Calithera Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	-$39.65M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Calithera Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALA Calithera Biosciences	N/A	$0.00 flat	N/A	N/A	$2K	N/A	N/A	60	Gap Up
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2
ADTX Aditxt	0.6404 of 5 stars	$0.01 flat	N/A	-100.0%	$5K	$14.34K	N/A	60	Gap Up
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	N/A	$5K	N/A	0.00	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calithera Biosciences (CALA) Competitors

CALA vs. GNCA, PXMD, ADTX, ARDS, and GNCAQ

How does Calithera Biosciences compare to Genocea Biosciences?

Summary

How does Calithera Biosciences compare to PaxMedica?

Summary

How does Calithera Biosciences compare to Aditxt?

Summary

How does Calithera Biosciences compare to Aridis Pharmaceuticals?

Summary

How does Calithera Biosciences compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALA vs. The Competition

Calithera Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calithera Biosciences (CALA) Competitors

CALA vs. GNCA, PXMD, ADTX, ARDS, and GNCAQ

How does Calithera Biosciences compare to Genocea Biosciences?

Is CALA or GNCA more profitable?

Do institutionals and insiders believe in CALA or GNCA?

Does the media refer more to CALA or GNCA?

Which has better earnings and valuation, CALA or GNCA?

Which has more risk and volatility, CALA or GNCA?

Summary

How does Calithera Biosciences compare to PaxMedica?

Is PXMD or CALA more profitable?

Do institutionals and insiders hold more shares of PXMD or CALA?

Which has more volatility and risk, PXMD or CALA?

Which has preferable earnings and valuation, PXMD or CALA?

Does the media prefer PXMD or CALA?

Summary

How does Calithera Biosciences compare to Aditxt?

Which has better earnings and valuation, ADTX or CALA?

Is ADTX or CALA more profitable?

Which has more risk & volatility, ADTX or CALA?

Do institutionals & insiders have more ownership in ADTX or CALA?

Do analysts recommend ADTX or CALA?

Does the media refer more to ADTX or CALA?

Summary

How does Calithera Biosciences compare to Aridis Pharmaceuticals?

Does the media favor ARDS or CALA?

Which has stronger valuation & earnings, ARDS or CALA?

Do institutionals and insiders have more ownership in ARDS or CALA?

Is ARDS or CALA more profitable?

Which has more risk and volatility, ARDS or CALA?

Summary

How does Calithera Biosciences compare to Genocea Biosciences?

Does the media prefer GNCAQ or CALA?

Which has stronger earnings & valuation, GNCAQ or CALA?

Which has more volatility and risk, GNCAQ or CALA?

Is GNCAQ or CALA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALA vs. The Competition

Calithera Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools